ArticleAmerican journal of hematology2021
An artificial intelligence-assisted diagnostic platform for rapid near-patient hematology.
Article in American journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- Hemoscreen Point-of-Care Analyzer Compared With Sysmex XN-1000 for Complete Blood Count in Pediatric Inpatients Aged 2 Months to 17 Years.International journal of laboratory hematology · 2026Article
- Clinical Evaluation of a Novel Point-of-Care Hematology Analyzer for Complete Blood Count With Differential.International journal of laboratory hematology · 2026Article
- AI-Supported Digital Microscopy Diagnostics in Primary Health Care Laboratories: Scoping Review.Journal of medical Internet research · 2026Article
- Artificial Intelligence in Haematologic Diagnostics: Current Applications and Future Perspectives.Acta haematologica · 2026Review
- Application of artificial intelligence in laboratory hematology: Advances, challenges, and prospects.Acta pharmaceutica Sinica. B · 2025Review
- Machine learning in point-of-care testing: innovations, challenges, and opportunities.Nature communications · 2025Review
- Complete blood count in neonatal Intensive care Unit (NICU): Performance comparison between POCT Sight OLO® and Sysmex XN-9100™ hematology analyzers.Practical laboratory medicine · 2025Article
- Ultrasound-based deep learning radiomics for multi-stage assisted diagnosis in reducing unnecessary biopsies of BI-RADS 4A lesions.Quantitative imaging in medicine and surgery · 2025Article
- A prospective study for the examination of peripheral blood smear samples in pediatric population using artificial intelligence.Turkish journal of medical sciences · 2025Article
- Home self-testing of complete blood counts in patients with breast cancer during chemotherapy: A proof-of-concept cohort study in e-oncology.Acta oncologica (Stockholm, Sweden) · 2024Article
- Preliminary Evidence of the Use of Generative AI in Health Care Clinical Services: Systematic Narrative Review.JMIR medical informatics · 2024Review
- Artificial Intelligence in Point-of-Care Testing.Annals of laboratory medicine · 2023Review
- Capillary blood stability and analytical accuracy of 12 analytes stored in Microtainers®.Practical laboratory medicine · 2023Article
- Hilab System Device in an Oncological Hospital: A New Clinical Approach for Point of Care CBC Test, Supported by the Internet of Things and Machine Learning.Diagnostics (Basel, Switzerland) · 2023Article
- Developing inclusive digital health diagnostic for schistosomiasis: a need for guidance via target product profiles.Frontiers in parasitology · 2023Article
- Usability Evaluation of a Noninvasive Neutropenia Screening Device (PointCheck) for Patients Undergoing Cancer Chemotherapy: Mixed Methods Observational Study.Journal of medical Internet research · 2022Observational
- A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects.Journal of medical Internet research · 2022Review
- Hilab system, a new point-of-care hematology analyzer supported by the Internet of Things and Artificial Intelligence.Scientific reports · 2022Article
- Real-world evaluation of rapid and laboratory-free COVID-19 triage for emergency care: external validation and pilot deployment of artificial intelligence driven screening.The Lancet. Digital health · 2022Article
- An artificial intelligence-assisted diagnostic platform for rapid near-patient hematology.American journal of hematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19-parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-fingerprick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.